Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consort, West Pharma Exubera alliance

This article was originally published in Clinica

Executive Summary

Consort Medical and West Pharmaceutical Services have ended their respective manufacturing and supply deals with Nektar Therapeutics for the Exubera insulin inhaler. Consort is set to receive £11m ($21.6m) from Nektar, while West Pharma did not disclose the amount that it would receive. San Carlos, California-based Nektar is required to pay Consort for reimbursement of costs and expenses under the terms of the original agreement, while West Pharma said that it would be reimbursed for facility, inventory, raw materials and personnel costs. Nektar holds the intellectual property to Exubera and the original agreement saw Consort (Milton Keynes, UK) and West Pharma (Lionville, Pennsylvania) manufacture the device. Manufacturing of the technology was ceased last October by Pfizer (who produced the insulin used in the devices) due to poor sales of the device. Analysts predicted last November that it would be Nektar, rather than Consort, West Pharma or Pfizer that would bear the brunt of the financial fallout from the ailing sales (see Clinica No 1279, p 12).

You may also be interested in...



Breckenridge Eyes First Kyprolis Generic With FDA Approval

Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.

Nestlé Sees Importance Of Local Brands In ‘Fragmented’ VMS Market

As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.

Lupin Gets Another First With Fostair

Lupin has claimed a first with a UK approval for a rival to Fostair. The Indian company has told Generics Bulletin that it is planning to roll out the Luforbec branded generic later this year.

Topics

UsernamePublicRestriction

Register

MT046125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel